Beam Therapeutics (BEAM): initial Phase I/II BEAM-301 data in GSD type 1a
FROM THE WIRE · SEEKINGALPHA.COM
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a October 27, 2026 8:00 AM EDTCompany...
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralEarly clinical data can move a biotech stock depending on the efficacy shown.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Beam Therapeutics presented initial Phase I/II data for BEAM-301.
- 02The study concerns glycogen storage disease type 1a.
- 03The presentation took place on October 27, 2026.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets